Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
OmniAb, Inc. is a biotechnology company that operates in the antibody discovery and early-stage drug development industry. The company provides proprietary transgenic animal platforms and discovery technologies that enable biopharmaceutical companies to generate fully human antibodies and antibody-based therapeutics. OmniAb’s business model is primarily platform-based, supporting drug discovery rather than developing its own therapeutic pipeline, which differentiates it from traditional biotech companies and reduces clinical and regulatory risk exposure.
The company generates revenue through access fees, research services, milestone payments, and downstream royalties tied to partner-developed products. OmniAb serves a global customer base that includes large pharmaceutical companies, mid-sized biotechnology firms, and emerging biotechs. The company was formed as a standalone public entity in 2022 following its separation from Ligand Pharmaceuticals Incorporated, where the OmniAb platform had been incubated and developed over multiple decades as a core discovery engine.
Business Operations
OmniAb operates through two primary business segments: Discovery Services and Royalty & Licensing. The Discovery Services segment provides partners with access to OmniAb’s proprietary transgenic animal platforms, including genetically engineered rats, mice, and chickens, along with antibody discovery, screening, and optimization services. The Royalty & Licensing segment captures long-term value through milestone payments and royalties on approved therapeutics that originate from OmniAb-enabled discovery programs.
Operations are primarily research-driven, with laboratory facilities and scientific teams supporting partners globally. OmniAb controls a portfolio of patented transgenic platforms and antibody engineering technologies. The company maintains collaborative relationships with numerous pharmaceutical and biotechnology partners, and its intellectual property estate underpins long-duration revenue potential tied to partner clinical and commercial success.
Strategic Position & Investments
OmniAb’s strategic direction centers on expanding adoption of its antibody discovery platforms, increasing the number of partnered programs, and growing its downstream royalty portfolio. The company focuses on high-value therapeutic areas such as oncology, immunology, inflammation, and rare diseases, where antibody-based drugs have demonstrated strong clinical and commercial outcomes.
Rather than pursuing large acquisitions, OmniAb’s investment strategy emphasizes internal platform innovation, expansion of transgenic capabilities, and selective technology enhancements that improve discovery efficiency and antibody diversity. The company’s long-term value proposition is driven by a growing portfolio of partnered assets progressing through clinical development, which may generate recurring milestone and royalty revenue over extended time horizons.
Geographic Footprint
OmniAb is headquartered in the United States, with core operations and research facilities primarily based in California. The company supports a broad international customer base, with partners operating across North America, Europe, and Asia-Pacific. While OmniAb does not maintain extensive overseas infrastructure, its platforms are deployed globally through licensing and research collaborations.
The company’s international influence is primarily investment- and partnership-driven rather than asset-heavy, allowing it to scale globally without significant geographic expansion of physical operations. This model enables OmniAb to maintain operational efficiency while participating in worldwide biopharmaceutical innovation.
Leadership & Governance
OmniAb is led by an executive team with experience in biotechnology platform development, licensing-based business models, and public company governance. The leadership emphasizes capital efficiency, long-term royalty generation, and scientific excellence as core strategic principles.
Key executives include:
- Matthew W. Foehr – Chairman of the Board and Chief Executive Officer
- Robert J. Stover – Chief Financial Officer
The company operates under a board and governance structure established following its spin-off from Ligand Pharmaceuticals Incorporated, with a strategic focus on transparency, disciplined capital allocation, and maximizing shareholder value through platform-driven growth.